Clinical significance of microRNA-130b in osteosarcoma and in cell growth and invasion  by Yu, Lie-Dao et al.
HOSTED BY Contents lists available at ScienceDirect
Asian Paciﬁc Journal of Tropical Medicine 2015; 8(9): 752–756752Asian Paciﬁc Journal of Tropical Medicine
journal homepage: http://ees.elsevier.com/apjtmOriginal research http://dx.doi.org/10.1016/j.apjtm.2015.07.026*Corresponding author: Jing-Yu Du, Department of Orthopedics, The First
Afﬁliated Hospital of Zhejiang University, No. 79 Qingchun Road, Hangzhou
310006, Zhejiang, China.
Tel: +86 13682178701
E-mail: dujingyu24324@163.com
Peer review under responsibility of Hainan Medical College.
1995-7645/Copyright © 2015 Hainan Medical College. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open ac
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Clinical significance of microRNA-130b in osteosarcoma and in cell growth and invasionLie-Dao Yu, Ri-Long Jin, Peng-Cheng Gu, Zhi-Heng Ling, Xiang-Jin Lin, Jing-Yu Du*Department of Orthopedics, The First Afﬁliated Hospital of Zhejiang University, No. 79 Qingchun Road, Hangzhou 310006, ChinaARTICLE INFO
Article history:
Received 15 Jun 2015
Received in revised form 20 Jul 2015
Accepted 20 Jul 2015
Available online 29 July 2015
Keywords:
MicroRNA-130b
Osteosarcoma
Tumor growth
Invasion
Clinical signiﬁcanceABSTRACT
Objective: To investigate clinical signiﬁcance of microRNA-130b (miR-130b) in oste-
osarcoma and its role in cell growth and invasion.
Methods: miR-130b expression was detected in 68 samples of surgically resected os-
teosarcoma and matched normal tumor-adjacent tissues by qRT-PCR. The expression of
miR-130b was altered by corresponding vectors in osteosarcoma cells, and then Western
blot was used to detect the expression of PPARg. BrdU cell proliferation and Transwell
assays were performed to determine cell proliferation and invasion.
Results: The expression of miR-130b in osteosarcoma tissues was signiﬁcantly higher
than that in normal tumor-adjacent tissues. Its expression in patients with metastasis was
signiﬁcantly higher than that in those without metastases. miR-130b expression in tumor
tissues was signiﬁcantly associated with tumor size, clinical stage and distant metastasis.
And its expression was signiﬁcantly correlated with overall survival and disease free
survival. miR-130b overexpression obviously repressed the expression of PPARg, and
resulted in signiﬁcant increase of Saos-2 cell proliferation and invasion. On the contrast,
repressing miR-130b expression with its inhibitor signiﬁcantly increased PPARg
expression, and inhibited MG-63 cell proliferation and invasion.
Conclusions: The high-expression of miR-130b is correlated with the adverse clinico-
pathological features and poor prognosis in osteosarcoma. miR-130b may regulate pro-
liferation and invasion of osteosarcoma cells by targeting PPARg, suggesting miR-130b
may play a key role in the progression of osteosarcoma.1. Introduction
Osteosarcoma is the most common type of primary malignant
tumor of bone, accounting for 60% of all malignant bone tumors
in teenage [1]. With the advancement of multiple therapeutic
strategies for osteosarcoma including surgical resection,
adjuvant chemotherapy and radiotherapy, the 5 year survival
of the non-metastatic patients has improved to approximately
60%–70% [2,3]. However, for patients with metastasis or
recurrence, the efﬁcacy of chemotherapy is signiﬁcantly
decreased, and the long-term prognosis remains poor with a
survival rate of 5%–20% [3]. Therefore, identifying novel
biomarkers and clarifying the molecular mechanisms of the
metastasis and recurrence of osteosarcoma may greatly
improve the prognosis of osteosarcoma patients.MicroRNAs (miRNAs) are a large group of non-coding
RNAs containing 18–25 nucleotides and post-transcriptionally
regulate the expression of multiple genes by interacting with
their 30-untranslated regions. Numerous deregulated miRNAs
have been found to play fundamental roles in the development
and progression of malignant diseases [4–10] including cell
growth, differentiation, invasion, metastasis, and angiogenesis.
Studies of melanoma [11], gastric carcinoma [12,13], bladder
cancer [14] and colorectal cancer [15] have shown that
aberrantly elevated miR-130b expression in these malignancies
was correlated with poor prognosis of patients, indicating an
oncogenic role of miR-130b in human cancers. In colorectal
cancer, miR-130b has been found to promote the migration and
invasion of cancer cells by targeting PPARg [15]. However, the
clinical signiﬁcance of miR-130b expression in osteosarcoma
tissues and its functional role on the migration and invasion of
osteosarcoma cells have not been examined.
In this study, we evaluated the expression of miR-130b in
osteosarcoma tissues by qPCR. Our results conﬁrmed that miR-
130b expression was signiﬁcantly increased in osteosarcoma
tissues. And its elevated expression was closely associated withcess article under the CC BY-NC-ND
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tumor size, advanced TNM stage, and distal metastasis.
Furthermore, in vitro experiments showed that miR-130b could
promote the progression of osteosarcoma by promoting cell
proliferation and invasion. This study proposes that miR-130b
may be a promising biomarker and attractive therapeutic target
of osteosarcoma.
2. Material and methods
2.1. Patients and specimens
Cancerous tissues and adjacent non-tumor tissues (>3 cm
distance to the resection margin) were collected from 68 patients
who underwent curative resection of osteosarcoma. The clini-
copathological data of all enrolled patients were demonstrated in
Table 1. All clinical samples were used after obtaining informed
consent. All patients did not receive any blood transfusion, ra-
diation treatment, or chemotherapy. The protocols of this study
have been approved by the Ethics Committee of University.
2.2. Real-time quantitative PCR
Total RNA was isolated from clinical tissues by TRIZOL®
reagent (Life Technologies, Carlsbad, CA, USA) under the
guidance of operation instructions. The ﬁrst strand cDNA was
synthesized by the Revertid™ First Strand cDNA Synthesis Kit
(TaKaRa, Shiga, Japan). Two microliters of cDNA obtained
from each sample was ampliﬁed and quantiﬁed by real-time
PCR of TaqMan Human MiRNA Assay (Applied Bio-
systems). miR-130b expression relative to U6 was calculated by
the method of 2−DDCt.
2.3. Cell culture
Human osteosarcoma cell lines, Saos-2 and MG-63, were
purchased from American Type Culture Collection, and was
cultured in Dulbecco's modiﬁed Eagle medium (DMEM, Gibco,
USA), containing 10% fetal bovine serum (Gibco) in a humid-
iﬁed 5% CO2 incubator at 37 C. Cells at logarithmic growth
phase were collected for further experiments.Table 1
Correlation between clinicopathological characteristics and expression of mi
Characteristics No. of c
Gender Male 40
Female 28
Age (years) <24 49
25 19
Clinical stage I 27
II 34
III 7
T classiﬁcation T1 26
T2 42
M classiﬁcation M0 61
M1 7
Histology Conventional osteosarcoma 58
Others 10
Histological differentiation G1 27
G2 41
*P < 0.05.2.4. Transfection of miRNA mimics and inhibitors
MiRNA vectors including miR-130b expression vector
(miR10004680-1-5), the control vector for miR-130b
(miR01201-1-2), miR-130b inhibitor (miR20004680-1-5) and
the negative control for the miR-130b inhibitor (miR02201-1-2)
bought from RiboBio (RiboBio, Guangzhou, China). Cells were
seeded at 1 × 105 cells per well in a six-well plate and trans-
fected with miRNA vectors at a ﬁnal concentration of 50 nM by
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) under the
guidance of operation instructions. Total RNA and protein were
collected 3 d post-transfection for experimental analyses.
2.5. Western blot
RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1%
TritonX-100, 5 mM ethylenediaminetetraacetic acid) was used
to extract the proteins of cell lysates. Protein concentration was
determined using the BCA Kit (Pierce, IL, USA). Protein sam-
ples (20 mg) were separated by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis and transferred to a nitrocellulose
membrane. The blots were then probed with antibodies against
PPAR-g (1:1000; Cell Signaling Technology, MA, USA) and b-
actin (1:1500, Boster, Wuhan, China). Blots were then incu-
bated with the appropriate ﬂuorescent secondary antibody
(1:5000; Boster). Images were acquired by the Bio-Rad Gel
imaging system and analyzed by the software program as
speciﬁed by Bio-Rad.
2.6. Cell proliferation assay
Saos-2 or MG-63 cells were seeded at 5 × 103 cells per well in
a 96-well plate, and was transfected with miRNAs vectors.
Twenty-four after transfection, cell proliferation ability was
assessed with Proliferation ELISA, BrdU (5-bromodeoxyuridine)
(chemiluminescent) (Roche, USA).
2.7. Transwell assay
The invasion assay was performed in 24-well Transwell units
(BD Biosciences) with 8 um porosity polycarbonate ﬁlters. EachR-130b in the osteosarcoma patients (n = 68).
ases miR-130b P
High expressing no. Low expressing no.
29 11 0.108
15 13
34 15 0.194
10 9
13 14 <0.001*
24 10
7 0 0.012*
12 14
32 10
38 23 0.020*
6 1
39 19 0.487
5 5
13 14 0.407
31 10
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Lakes, NJ, USA) at 1 mg/mL on the inner layer. 1.5 × 105 Saos-
2 or MG-63 cells suspended in 200 mL reduced serum DMEM
medium were added into the upper chamber, and 800 mL
DMEM medium containing 20% FBS was added into the lower
chamber. After incubating for 24 h, cells were ﬁxed in 4%
paraformaldehyde for 3 min, and then permeabilized in meth-
anol for 20 min. Cells on the inner layer were removed with a
cotton swab, and the adherent cells on undersurface of the insert
were stained with 0.3% crystal violet dye for 10 min. The ﬁlters
were washed with PBS and images were taken. Invaded cells on
undersurface were counted under a light microscope.
2.8. Statistical analysis
All data are presented as mean ± SEM. The GraphPad Prism
5 software (GraphPad Software, Inc., San Diego, CA, USA) was
used for Pearson chi-square test and Two-tailed Student's t test.
Kaplan–Meier method was employed to plot overall survival
and disease-free survival curves, and the prognostic effect of
mIR-130b was evaluated using the log-rank test. P < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Elevated expression of miR-130b expression in
osteosarcoma tissues
Compared with that in matched non-tumor tissues, miR-130b
expression in tumor tissues was signiﬁcantly elevated (P < 0.05,Figure 1. Expression level of miR-130b in osteosarcoma tissues.
A) osteosarcoma tissues and matched non-tumor tissues; B) osteosarcoma tissu
Figure 2. Kaplan–Meier survival curves for osteosarcoma patients based on m
A) Overall survival rate (P < 0.05). B) Survival rate (P < 0.05).Figure 1A). The level of miR-130b in metastases group was
signiﬁcantly higher than that in non-metastases group (P < 0.05,
Figure 1B). These results suggest that miR-130b plays an
oncogenic role in osteosarcoma and is involved in the metastasis
of osteosarcoma.
3.2. Correlation between clinicopathological
characteristics and expression of miR-130b
As shown in Table 1, clinical association analysis by the
Pearson chi-square test demonstrated that increased expression
of miR-130b was signiﬁcantly correlated with large tumor size
(P = 0.020), advanced tumor stage (P < 0.001)and distal
metastasis (P = 0.020). These results indicate increased
expression of miR-130b is correlated with poor clinicopatho-
logical features in osteosarcoma. Patients with high miR-130b
level had signiﬁcantly decreased overall survival (P < 0.05,
Figure 2A) and disease free survival (P < 0.05, Figure 2B).
3.3. Overexpression of miR-130b promotes proliferation
and invasion of osteosarcoma cells
As shown in Figure 2, transfection of miR-130b expressing
plasmid resulted in signiﬁcantly increased level of miR-130b in
Saos-2 cells (Figure 3A, P < 0.05). Moreover, PPARg, a well-
deﬁned downstream target of miR-130b in colorectal cancer
cells, was signiﬁcantly down-regulated accordingly (Figure 3B,
P < 0.05). And Brdu incorporation assay and transwell assay
demonstrated overexpression of miR-130b in Saos-2 cells
resulted in signiﬁcantly increased proliferation (Figure 3C,es arising from metastases and non-metastases groups. *P < 0.05.
iR-130b level.
Figure 3. PPARg expression, cell proliferation and invasion in Saos-2 cells.
A) miR-130b level in Saos-2 cells. n = 6, *P < 0.05; B) PPARg expression in Saos-2 cells. n = 6, *P < 0.05; C) Cell proliferation and invasion in Saos-2
cells. n = 6, *P < 0.05; D). Cell invasion in Saos-2 cells. n = 6, *P < 0.05.
Figure 4. PPARg expression, cell proliferation and invasion in MG-63 cells.
A) miR-130b level in MG-63 cells. n = 6, *P < 0.05; B) PPARg expression in MG-63 cells. n = 6, *P < 0.05; C) Cell proliferation in MG-63 cells. n = 6,
*P < 0.05; D) Cell invasion in MG-63 cells. n = 6, *P < 0.05.
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respectively.
3.4. Down-regulation of miR-130b inhibits proliferation
and invasion of osteosarcoma cells
The expression of miR-130b was signiﬁcantly reduced after
transfecting its inhibitor into MG-63 cells (Figure 4A, P < 0.05).
And the expression of PPARg was signiﬁcantly increased after
down-regulating miR-130b (Figure 4B, P < 0.05). Functionally,
after repressing the expression of miR-130b, decreased prolif-
eration (Figure 4C, P < 0.05) and invasion (Figure 4D,
P < 0.05) of MG-63 cells were observed.
4. Discussion
MiRNAs can regulate gene expression at post-transcriptional
level by binding to 30-untranslated regions of target messenger
RNAs (mRNAs), and thus participate in many critical biological
processes including cell differentiation, morphogenesis and
tumorigenesis [16,17]. The critical role of miRNAs in the
development and progression of human cancers have beenwidely accepted. miRNAs can play either oncogenic role or
tumor suppressive role in human malignancies [18–20]. Moreover,
miRNAs have been regarded as promising biomarkers and
attractive therapeutic targets for human cancers [21].
MiR-130b is being actively investigated in many kinds of
human cancers [11–15,22–25]. It has been found to be down-
regulated in papillary thyroid carcinoma [22], endometrial
cancer [23], pituitary adenomas [24] and pancreatic cancer [25].
However, in melanoma [11], gastric carcinoma [12,13], bladder
cancer [14], and colorectal cancer [15], miR-130b expression
was found to be aberrantly elevated. Increased level of miR-
130b in the serum of colon cancer patients was associated
with resistance to chemotherapy [26]. And miR-130b has been
regarded as an effective biomarker for HCC patients [27,28]. In
this study, we evaluated the expression status of miR-130b in
68 pairs of osteosarcoma tissues and adjacent non-tumor tissues
using qRT-PCR. The result revealed a signiﬁcant increase of
miR-130b expression in osteosarcoma tissues. Furthermore, we
investigated the clinical signiﬁcance of miR-130b in osteosar-
coma. Clinical association analysis proved that miR-130b was
closely associated with large tumor size, advanced TNM stage
and distal metastasis. Moreover, increased level of miR-130b
Lie-Dao Yu et al./Asian Paciﬁc Journal of Tropical Medicine 2015; 8(9): 752–756756was correlated with poorer prognosis of osteosarcoma patients.
These results indicate that miR-130b serves as an oncogenic
miRNA in osteosarcoma and can potentially act as a novel
biomarker of the prognosis of osteosarcoma patients.
Previous study demonstrated that miR-130b could down-
regulate PTEN, E-cadherin, Snail and VEGF by inhibiting
PPARg, and thus resulted in increased proliferation, EMT and
angiogenesis of colorectal cancer [15]. In endometrial cancer,
miR-130b could contribute to EMT of cancer cells by target-
ing DICER1 [29]. This study demonstrated that overexpression
of miR-130b in MG-63 cells could inhibit the expression of
PPARg which was found to be down-regulated in osteosarcoma
and could regulate proliferation, invasion and resistance to
chemotherapy [30,31]. Accordingly, our functional experiments
conﬁrmed that overexpressing miR-130b led to increased pro-
liferation and invasion of Saos-2 cells. On the other way, down-
regulating miR-130b resulted in elevation of PPARg expression,
and decreased proliferation and invasion in MG-63 cells. These
results indicate that miR-130b may promote the growth and
metastasis of osteosarcoma by repressing PPARg.
In summary, our results demonstrate that miR-130b is up-
regulated in osteosarcoma, and its elevated expression is asso-
ciated with large tumor size, distal metastasis and advanced TNM
stage. Patients with increased level of miR-130b have a signiﬁ-
cantly poorer prognosis. Functionally, miR-130b may promote
the proliferation and invasion of osteosarcoma cells by targeting
PPARg, and thus contributes to the development and progression
of osteosarcoma. This study indicates that miR-130b may be a
promising biomarker and therapeutic target in osteosarcoma.
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